PROFILPELAJAR.COM

Piribedil
(IUPAC) ime
	2-[4-(benzo[1,3]dioksol-5-ilmetil)piperazin-1-il]pirimidin
Klinički podaci
AHFS/Drugs.com	Internacionalno ime leka
Identifikatori
CAS broj	3605-01-4
ATC kod	N04BC08
PubChem	4850
UNII	DO22K1PRDJ
KEGG	D07305
ChEMBL	CHEMBL1371770
Hemijski podaci
Formula	C16H18N4O2
Mol. masa	298,340 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2 ; Key: OQDPVLVUJFGPGQ-UHFFFAOYSA-N
Farmakokinetički podaci
Poluvreme eliminacije	1,7-6,9 sata
Izlučivanje	Renalno (68%) i bilijarno (25%)
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	℞ Prescription only
Način primene	Oralno

Piribedil (Trivastal, Pronoran, Trastal, Trivastan) je antiparkinsonski agens derivat piperazina koji deluje kao agonist D₂ i D₃ receptora. On isto tako deluje kao antagonist α₂-adrenergičkog receptora.^[5]^[6]

Indikacije

Treatman Parkinsonove bolesti, bilo putem monoterapije (bez L-DOPA (Levodope)), ili u kombinaciji sa L-DOPA terapijom.
Treatman patološkog kognitivnog deficita kod starih osoba.
Treatman nesvestice kod starijih osoba.
Treatman retinalnih ishemijskih manifestacija.

Izvori

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Millan MJ, Cussac D, Milligan G, et al. (June 2001). „Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization”. The Journal of Pharmacology and Experimental Therapeutics 297 (3): 876–87. PMID 11356907. Arhivirano iz originala na datum 2019-12-14. Pristupljeno 2014-04-05.
↑ Gobert A, Di Cara B, Cistarelli L, Millan MJ (April 2003). „Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors”. The Journal of Pharmacology and Experimental Therapeutics 305 (1): 338–46. DOI:10.1124/jpet.102.046383. PMID 12649387. Arhivirano iz originala na datum 2019-12-14. Pristupljeno 2014-04-05.

Vanjske veze

	Portal Medicina
	Portal Hemija

Piribedil Arhivirano 2019-07-27 na Wayback Machine-u

Povezano

<!Antiparkinson>

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[pmid11356907-5] Millan MJ, Cussac D, Milligan G, et al. (June 2001). „Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization”. The Journal of Pharmacology and Experimental Therapeutics 297 (3): 876–87. PMID 11356907. Arhivirano iz originala na datum 2019-12-14. Pristupljeno 2014-04-05.

[pmid12649387-6] Gobert A, Di Cara B, Cistarelli L, Millan MJ (April 2003). „Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors”. The Journal of Pharmacology and Experimental Therapeutics 305 (1): 338–46. DOI:10.1124/jpet.102.046383. PMID 12649387. Arhivirano iz originala na datum 2019-12-14. Pristupljeno 2014-04-05.

[1]

[2]

[3]

[4]

[5]

[6]